Compare Oracle Corporation (ORCL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Oracle Corporation trades at $125.9 (market cap $365.96B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Oracle Corporation is far larger — about 3× Vertex Pharmaceuticals Incorporated's market cap, and Oracle Corporation pays a 1.57% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ORCL | VRTX | |
|---|---|---|
Market Cap | $365.96B | $122.33B |
Sector | Technology | Health |
52-Week High | $328.33 | $529.59 |
52-Week Low | $121.37 | $366.54 |
Enterprise Value | $495.21B | $117.07B |
Dividend Yield | 1.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) trades at $125.86, up 3.7% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 21.67% net margins and consistent revenue growth. Recent AI partnerships and infrastructure investments position Oracle as a key player in the enterprise cloud and AI markets, though high valuation multiples and significant debt levels warrant caution.
Oracle presents a compelling growth story driven by AI infrastructure demand, with analyst consensus strongly bullish (65% buy ratings) and a $253.30 price target representing significant upside. Key risks include high leverage, competitive pressures, and execution challenges in capital-intensive AI expansion. The upcoming Q2 2026 earnings report on June 10 will be critical for validating the AI growth narrative.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
